Showing 1 - 10 of 19
Persistent link: https://www.econbiz.de/10010425165
Persistent link: https://www.econbiz.de/10003568959
Persistent link: https://www.econbiz.de/10009710440
Persistent link: https://www.econbiz.de/10010380923
Persistent link: https://www.econbiz.de/10003841134
Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation. Public prescription drug insurance escapes that trade-off and achieves an elusive goal: lowering static deadweight loss, while simultaneously encouraging dynamic investments in...
Persistent link: https://www.econbiz.de/10012775801
Effectively designed market mechanisms may reduce growth in health care spending. In this paper, we study the impact of privatizing the delivery of Medicaid drug benefits on drug spending. Exploiting granular data that allow us to examine drug utilization, we find that drug spending would fall...
Persistent link: https://www.econbiz.de/10012945134
Prior research has shown that exogenous shocks to the demand for medical products spur additional product development. These studies do not distinguish between breakthrough products and those that largely duplicate the performance of existing products. In this paper, we use a novel data set to...
Persistent link: https://www.econbiz.de/10013033384
Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation. Public prescription drug insurance escapes that trade-off and achieves an elusive goal: lowering static deadweight loss, while simultaneously encouraging dynamic investments in...
Persistent link: https://www.econbiz.de/10012465145
Persistent link: https://www.econbiz.de/10012415052